Investor webinars, news coverage, and media resources from Nexalis Therapeutics and our clinical programs.
Investor Webinars
February 2026 Investor Webinar
February 2026
Watch the replay of our investor webinar covering the latest clinical updates and company progress.
Press & News
Nexalis Oral Esketamine Gains Regulatory Tailwind From U.S. Policy Shift
Nexalis Therapeutics' SRX-25 oral esketamine therapy benefits from a U.S. Executive Order designed to accelerate mental health treatment approvals, with the company's FDA 505(b)(2) pathway positioning it to address treatment-resistant depression care.
Read articleNexalis Therapeutics (ASX: NX1) Commences Phase 2 Trial for Breakthrough Cancer Pain Treatment
Phase 2 trial of inhaled IRX-211 commences, targeting breakthrough cancer pain in opioid-tolerant patients.
Read articleNexalis (formerly InhaleRx) Initiates Phase 1 Trial of IRX-616a CBD MDI
Nexalis initiates Phase 1 testing of IRX-616a, an inhaled cannabidiol therapy for panic disorder.
Read articleFirst Eligible Participant Screened — Phase 1 IRX-616a Study
ASX announcement confirming first eligible participant screened and recruited in the Phase 1 IRX-616a study.
Read articleNexalis Therapeutics Begins Phase 1 Trial of IRX-616a for Panic Disorder
Nexalis begins Phase 1 clinical trial evaluating inhaled CBD treatment IRX-616a for panic disorder.
Read articleNexalis Outlines 2026 Plan as IRX Shares Jump 35%
Nexalis Therapeutics presents its 2026 strategic outlook as ASX-listed shares surge over 35%.
Read articleASX: NX1 — Price-Sensitive Announcements
Track all ASX price-sensitive announcements from Nexalis Therapeutics (NX1) on Intelligent Investor.
Read articleReports & Presentations
Investor presentations and reports will be published here.
View Investor Relations →